Dyne Therapeutics Inc
DYN9.400USD
+0.070+0.75%
Close 07/17, 16:00（ET）Quotes delayed by 15 min
1.07BMarket Cap
LossP/E TTM
More Details of Dyne Therapeutics Inc Company
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Company Info
Ticker SymbolDYN
Company nameDyne Therapeutics Inc
IPO dateSep 17, 2020
Founded at2013
CEOMr. John Cox
Number of employees191
Security typeOrdinary Share
Fiscal year-endSep 17
Address1560 Trapelo Road
CityWALTHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02451
Phone17817868230
Websitehttps://dyne-tx.com/
Ticker SymbolDYN
IPO dateSep 17, 2020
Founded at2013
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Carlo Incerti, M.D.
Dr. Carlo Incerti, M.D.
Independent Director
Independent Director
--
--
Mr. Dirk Kersten
Mr. Dirk Kersten
Independent Director
Independent Director
--
--
Dr. Doug Kerr
Dr. Doug Kerr
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John Cox
Mr. John Cox
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
97.96K
+158.06%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
89.47K
--
Dr. Oxana Beskrovnaya, Ph.D.
Dr. Oxana Beskrovnaya, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
43.00K
-65.20%
Mr. Erick J. Lucera
Mr. Erick J. Lucera
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. David C. Lubner
Mr. David C. Lubner
Independent Director
Independent Director
--
--
Ms. Johanna Friedl- Naderer
Ms. Johanna Friedl- Naderer
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
7.51%
RA Capital Management, LP
7.05%
Atlas Venture
6.62%
The Vanguard Group, Inc.
5.36%
BlackRock Institutional Trust Company, N.A.
4.54%
Other
68.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
27.04%
Venture Capital
20.92%
Investment Advisor
19.50%
Hedge Fund
15.36%
Private Equity
3.46%
Research Firm
2.73%
Sovereign Wealth Fund
0.69%
Individual Investor
0.61%
Corporation
0.22%
Other
9.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
430
125.53M
91.24%
+6.97M
2025Q1
444
126.02M
110.93%
+6.11M
2024Q4
417
114.24M
101.08%
-7.86M
2024Q3
400
113.88M
111.83%
-6.47M
2024Q2
373
112.89M
113.78%
+7.88M
2024Q1
324
97.50M
111.98%
+21.84M
2023Q4
282
72.67M
118.28%
-4.07M
2023Q3
268
67.80M
111.02%
+90.07K
2023Q2
267
66.99M
114.89%
+4.15M
2023Q1
269
62.13M
106.57%
+3.08M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
10.35M
7.51%
+2.97M
+40.30%
Mar 31, 2025
RA Capital Management, LP
9.71M
7.05%
+3.33M
+52.24%
Mar 31, 2025
Atlas Venture
9.13M
6.62%
+1.11M
+13.86%
Mar 31, 2025
The Vanguard Group, Inc.
7.39M
5.36%
+697.86K
+10.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.26M
4.54%
+96.01K
+1.56%
Mar 31, 2025
Forbion Capital Partners
5.46M
3.96%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.19M
3.77%
-2.39M
-31.52%
Mar 31, 2025
Braidwell LP
3.62M
2.63%
+2.94M
+431.63%
Mar 31, 2025
State Street Global Advisors (US)
3.61M
2.62%
-107.73K
-2.90%
Mar 31, 2025
Citadel Advisors LLC
3.01M
2.18%
+147.81K
+5.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
2.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.62%
Tema Neuroscience and Mental Health ETF
0.55%
SPDR S&P Biotech ETF
0.28%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Invesco Nasdaq Biotechnology ETF
0.15%
iShares Health Innovation Active ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.12%
Optimize Strategy Index ETF
0.12%
iShares Biotechnology ETF
0.11%
View more
iShares Neuroscience and Healthcare ETF
Proportion2.39%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.62%
Tema Neuroscience and Mental Health ETF
Proportion0.55%
SPDR S&P Biotech ETF
Proportion0.28%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.26%
Invesco Nasdaq Biotechnology ETF
Proportion0.15%
iShares Health Innovation Active ETF
Proportion0.14%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Optimize Strategy Index ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
